Treatment of disseminated granuloma annulare with fumaric acid esters by Kreuter, Alexander et al.
BioMed  Central
Page 1 of 4
(page number not for citation purposes)
BMC Dermatology
BMC Dermatology  2002,  2 x Case report
Treatment of disseminated granuloma annulare with fumaric acid 
esters
Alexander Kreuter, Thilo Gambichler*, Peter Altmeyer and 
Norbert H Brockmeyer
Address: Department of Dermatology, Ruhr-University Bochum, Gudrunstrasse 56, 44791 Bochum, Germany
E-mail: Alexander Kreuter - a.kreuter@derma.de; Thilo Gambichler* - t.gambichler@derma.de; Peter Altmeyer - p.altmeyer@derma.de; 
Norbert H Brockmeyer - n.brockmeyer@derma.de
*Corresponding author
Abstract
Background: Granuloma annulare is a granulomatous disease of unknown etiology. Various
therapies have been tried in disseminated granuloma annulare (DGA), including corticosteroids,
several variants of psoralen plus ultraviolet-A radiation, ultraviolet- A1 radiation, systemic
retinoids, and dapsone, with variable success. We report a patient with recalcitrant DGA who was
treated with fumaric acid esters (FAE).
Case presentation: A 40-year old Caucasian woman presented with a 25-year history of
recalcitrant DGA. On both legs and the abdomen there were erythematous annular plaques. She
was treated with FAE in tablet form using two formulations differing in strength (low strength
tablets: 30 mg dimethylfumarate, 67 mg monoethylfumarate Ca salt, 5 mg monoethylfumarate Mg
salt, 3 mg monoethylfumarate Zn salt; high strength tablets: 120 mg dimethylfumarate, 87 mg
monoethylfumarate Ca salt, 5 mg monoethylfumarate Mg salt, 3 mg monoethylfumarate Zn salt).
After three-month therapy, an almost complete clearance of skin lesions was achieved. With the
exception of temporary lymphopenia, no adverse effects were observed. The patient remained in
remission during a six-month follow up period.
Conclusions: Our observation has demonstrated that FAE is a potentially beneficial therapeutic
option for patients with recalcitrant DGA. However controlled trials are necessary to fully explore
the efficacy, optimal dosage, and safety of FAE in the management of DGA.
Background
Granuloma annulare is a granulomatous disease of un-
known etiology. Disseminated granuloma annulare
(DGA) is characterized by a chronic course of disease and
frequent association with systemic disorders such as dia-
betes mellitus. Although spontaneous resolution can oc-
cur in some cases various therapies have been tried in
DGA, including corticosteroids, several variants of psor-
alen plus ultraviolet-A radiation, ultraviolet- A1 radiation,
systemic retinoids, and dapsone, with variable success [1–
5]. We report a patient with recalcitrant DGA who was
treated with fumaric acid esters (FAE).
Case presentation
A 40-year old Caucasian woman presented with a 25-year
history of DGA on both legs. Since one year, she also had
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lesions on the abdomen. Previous treatments with various
therapeutic modalities (e.g., corticosteroids, dapsone, and
bath psoralen plus ultraviolet-A radiation) were ineffec-
tive. On examination, she had erythematous annular
plaques on the abdomen and on both legs (Fig. 1). His-
topathologic examination of a punch biopsy specimen
from the left leg revealed a normal epidermis. Below the
epidermis there was mild collagen degeneration sur-
rounded by palisading inflammatory cells. The infiltrates
consisted of a mixture of monocytes, histiocytes, and oc-
casional giant cells. These findings were consistent with
the diagnosis of DGA. Complete work-up did not reveal
evidence of malignancies, infections, and internal diseas-
es such as diabetes mellitus.
Since the disease had been recalcitrant to various conven-
tional therapies, we decided to start oral treatment with
fumaric acid esters. The patient was treated with FAE in
tablet form using two formulations differing in strength
(low strength tablets: 30 mg dimethylfumarate, 67 mg
monoethylfumarate Ca salt, 5 mg monoethylfumarate Mg
salt, 3 mg monoethylfumarate Zn salt; high strength tab-
lets: 120 mg dimethylfumarate, 87 mg monoethylfuma-
rate Ca salt, 5 mg monoethylfumarate Mg salt, 3 mg
monoethylfumarate Zn salt), supplied as Fumaderm® ini-
tial and Fumaderm® (Fumedica GmbH, Herne, Germany)
[6]. Dosage of FAE was performed according to the stand-
ard therapy regimen for psoriasis patients displayed in Ta-
ble 1. After two months, a complete clearance of skin
lesions on the abdomen was achieved. Long-standing le-
sions on the legs improved after three-month therapy
(Fig. 2). No subjective side effects were observed during
treatment. Regular laboratory investigations, including
differentiate blood count and kidney function, did not re-
vealed abnormal findings during therapy, with the excep-
tion of slight lymphocytopenia. After discontinuation of
Figure 1
Long-standing disseminated granuloma annulare on the left
leg.
Figure 2
Almost complete clearance of disseminated granuloma annu-
lare after 3 months of therapy with fumaric acid esters.BMC Dermatology 2002, 2 http://www.biomedcentral.com/1471-5945/2/5
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treatment with FAE the patient remained in remission
during a six-month follow up period.
Discussion
FAE has been shown to be an effective therapy option in
patients with severe psoriasis vulgaris [6,7]. During thera-
py with fumaric acid a persistent decrease in the lym-
phocyte count and stimulation of TH2 cytokine responses
have been observed. Since psoriasis is regarded as a TH1-
type inflammatory disorder, the immunomodulation
away from the TH1 cytokine IFN-γ  to the TH2 cytokine IL-
10 may lead to improvement of the disease. Furthermore
the anipsoriatic activity of fumaric acid may also be medi-
ated by diminishing proinflammatory cytokine overex-
pression and the antigen-presenting capacity of
monocytes and macrophages [8,9].
It has been reported that FAE induce apoptosis in human
dentritic cells as well as keratinocytes [10]. Histopatholog-
ically, localized granuloma as well as DGA are character-
ized by lymphohistiocytic and monocytic infiltrates that
form palisading granulomas with central necrobiotic
changes. In a recent study, numerous apoptotic macro-
phages have been observed within the necrobiotic areas
[11]. A popular view concerning pathogenesis holds that
granuloma annulare is based on a delayed-type hypersen-
sitivity reaction to as yet undefined cutaneous antigens.
Phototherapy (e.g., psoralen plus ultraviolet-A radiation,
ultraviolet- A1 radiation) is effective in DGA and is known
to suppress delayed hypersensitivity responses in the skin
[3–5]. Previous findings suggest that a T cell-mediated im-
mune response producing cytokines may be the dominant
pathogenic factor in granuloma annulare [12]. Thus the
efficacy of FAE in DGA may be mediate by similar immu-
nomodulatory mechanisms that are observed in the treat-
ment of psoriasis. Notably it has been observed that
treatment with FAE was also effective in cutaneous sar-
coidosis and necrobiosis lipoidica which are closely relat-
ed to granuloma annulare U. Nowack, MD, and T.
Gambichler, MD; unpublished data). Schulze-Dirks and
Petzoldt [13] reported a female with a one-year history of
DGA which resolved after six-week treatment of FAE.
Since our patient had long-standing DGA, which was re-
calcitrant to potentially helpful therapeutic modalities, we
do not consider that the therapeutic effect was due to
spontaneous resolution. It has been demonstrated that
FAE are well tolerated drugs suitable for long-term man-
agement (> 6 months) in psoriasis. Subjective adverse ef-
fects such as flushing and gastrointestinal symptoms are
frequently observed. Relative lymphocytopenia is the
most frequent laboratory finding in long-term users.
Therefore therapy with FAE should only be performed un-
der controlled conditions [14]. FAE are a potentially ben-
eficial therapeutic option for patients with recalcitrant
DGA. Controlled trials are however necessary to fully ex-
plore the efficacy, optimal dosage, and safety of FAE in the
treatment of DGA.
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